Compare ORBS & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ORBS | HELP |
|---|---|---|
| Founded | 1966 | N/A |
| Country | United States | Canada |
| Employees | 9 | 50 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 262.0M | 233.0M |
| IPO Year | N/A | N/A |
| Metric | ORBS | HELP |
|---|---|---|
| Price | $0.60 | $7.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $51.50 |
| AVG Volume (30 Days) | ★ 11.9M | 2.0M |
| Earning Date | 04-14-2026 | 07-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.57 | $3.76 |
| 52 Week High | $15.96 | $8.55 |
| Indicator | ORBS | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 37.44 | 62.04 |
| Support Level | N/A | $4.18 |
| Resistance Level | $1.23 | $8.55 |
| Average True Range (ATR) | 0.05 | 0.54 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 21.37 | 59.70 |
Eightco Holdings Inc operates in Forever 8 Inventory Cash Flow Solution. The company is a dynamic technology-focused company committed to driving growth and innovation through strategic acquisitions and management. Forever 8 focuses on purchasing inventory for e-commerce retailers and is part of its Inventory Solution Business. Corrugated Packaging Business manufactured and sold custom packaging for a wide products and through packaging helps customers generate brand awareness and promote brand image. Generate the substantial majority of revenues from inventory financing and inventory management services.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.